Clinical trial of lamivudine in children with chronic hepatitis B

New England Journal of Medicine

Volumn 346, Issue 22, 2002, Pages 1706-1713

  Jonas, Maureen M ^a   Kelley, Deirdre A ^b   Mizerski, Jacek ^c   Badia, Isabel B ^d   Areias, Jorge A ^e   Schwarz, Kathleen B ^f   Little, Nancy R ^g   Greensmith, Martin J ^h   Gardner, Stephen D ^g   Steve Bell, M ^g   Sokal, Etienne M ⁱ  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^d HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^e HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g GLAXOSMITHKLINE   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SIDE EFFECT; VIRUS RESISTANCE;

ADOLESCENT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LOGISTIC MODELS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037198434     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012452     Document Type: Article

References (20)

1. Update on diagnosis, management, and prevention of hepatitis B virus infection
2. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: A birth order study
3. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
4. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B
5. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
6. Management of hepatitis B: 2000 - Summary of a workshop
7. A one-year trial of lamivudine for chronic hepatitis B
8. Lamivudine as initial treatment for chronic hepatitis B in the United States
9. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
10. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
11. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children
12. Bortolotti E Interferon-α treatment of chronic hepatitis B in childhood: A consensus advice based on experience in European children
13. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
14. The treatment of chronic viral hepatitis
15. Chronic hepatitis B virus infection: Treatment strategies for the next millennium
16. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial
17. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
18. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
19. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine